[ad_1]
LONDON, March 27, 2024 (GLOBE NEWSWIRE) — Lightpoint Surgical Limited (Lightpoint), an affiliate of Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), today announced the launch of the world’s first bladder cancer sentinel lymph node. (SLN) Surgery announced.with the teacher®, Telix’s small robot-assisted gamma-ray probe is used to detect radiation in patients and guide surgery. The patient underwent surgery at Del Mar Hospital in Barcelona, Spain.
SENSEI® is smaller than an AA battery and is specifically designed for minimally invasive robotic-assisted surgery. The small size and unique features make this technology ideal for tight surgical spaces such as perivesical areas.
SENSEI® has been widely applied in radiation-guided surgery across multiple surgeries and major cancer types, and is currently available for use during SLN biopsies in prostate, endometrial and cervical cancers. It has been adapted. As part of an investigator-initiated clinical trial, Dr. Lluís Cecchini, along with his da Vinci Xi surgical robotic platform, will present his SENSEI to patients scheduled for radical cystectomy with SLN biopsy and Bricker urinary diversion. ® was used.
Dr. Luis Cecchini, head of urology at Del Mar Hospital, said, “It is important to remove the lymph nodes around the bladder because they are more likely to be cancerous. “It has been limited by the fact that it is used extensively.” The size and flexibility of the SENSEI® made it easy to maneuver within the surgical cavity, allowing us to see the gamma signal within the robotic console and quickly locate SLNs whose presence we would otherwise have been unaware of. ”
Nynke van den Berg, general manager of medical technology (MedTech) at Telix, added: “The first bladder cancer surgery using the SENSEI® drop-in gamma probe is an important milestone for the Telix and Lightpoint teams. We are excited to align SENSEI® with our Illuccix® and TLX599-CDx programs for prostate cancer. This successful procedure demonstrates the potential and scope to expand its use to other urinary malignancies, in line with our portfolio approach of supporting patients from diagnosis to surgery. It’s intervention and treatment.”
About SENSEI®
Lightpoint has developed SENSEI®, a miniature surgical gamma probe for minimally invasive and robot-assisted surgery. The device is approved for sale in the US, EU, UK, and Australia and is in clinical use in the US, UK, Germany, France, Netherlands, Belgium, and Spain.
about light point
Lightpoint Surgical Ltd (Lightpoint) is an affiliate of Telix Pharmaceuticals Limited. As his MedTech division of Telix, Lightpoint is focused on developing precision guided surgical solutions and complementary artificial intelligence technologies to help detect, manage and treat cancer and rare diseases. Litepoint is headquartered in the UK.
Telix Investor Information
Kyan Williamson
TELIX PHARMACEUTICALS LIMITED.
Senior Vice President, Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
legal notice
The information contained in this announcement is not intended to be an offer, solicitation, or recommendation with respect to the shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representations or warranties, express or implied, are made as to the accuracy or completeness of the information contained or to the opinions expressed in the course of this publication. Information contained in this announcement is subject to change without notice.
This announcement may contain forward-looking statements relating to expected future events, financial performance, plans, strategies or business developments. Forward-looking statements generally include words such as “may”, “anticipates”, “intends”, “plans”, “estimates”, “anticipates”, “outlook”, “predicts”, “guidance”, etc. can be identified by the use of words such as “. , or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and risks that may affect our actual results, level of activity, performance or achievements, including any future results, activities expressed or implied by these forward-looking statements. and other factors that may cause the level, performance or results of the Company to differ materially. The statement you are looking for. Forward-looking statements are based on our good faith assumptions about financial, market, regulatory and other risks and considerations that will affect our business and operations in the future, and whether any of these assumptions will There is no guarantee that it will have an impact. I’ll prove you right. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements regarding: Telix’s preclinical and clinical studies and the initiation, timing, progress and results of Telix’s research and development programs; Telix’s ability to advance, enroll and successfully complete clinical studies, including multinational clinical trials, of its product candidates; the timing or potential of regulatory filings and approvals, manufacturing activities and product marketing activities; Telix’s product candidates will be commercialized if or at the time they are approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s Financial Performance. Telix’s competitors and industry trends; Pricing and Refunds If and After Telix’s Product Candidates Are Approved. Telix’s actual results, performance or achievements may differ materially from those expressed or implied by such statements, and such differences may be adverse to you. Therefore, you should not place undue reliance on these forward-looking statements. Please read this announcement together with our risk factors as disclosed in recent filings with the ASX or on our website.
To the fullest extent permitted by law, Telix does not intend to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments, or changes in expectations or assumptions. disclaims any obligation or undertaking to do so.
©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Lightpoint, Illuccix®, and SENSEI® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates, and all rights reserved.
[ad_2]
Source link
